NASDAQ:BIOT Biotech Acquisition (BIOT) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free BIOT Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$10.14▼$10.1950-Day Range$10.08▼$10.3252-Week Range$8.30▼$10.41Volume44,400 shsAverage Volume244,605 shsMarket Capitalization$291.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biotech Acquisition alerts: Email Address Ad Crypto 101 Media$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Biotech Acquisition Stock (NASDAQ:BIOT)Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.Read More Ad Crypto 101 Media$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. BIOT Stock News HeadlinesMay 29, 2024 | finance.yahoo.comJeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billionMay 29, 2024 | msn.comMerck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market PresenceMay 28, 2024 | bizjournals.comD.C.’s Vanda Pharmaceuticals rejects acquisition offer — againMay 23, 2024 | finance.yahoo.comResource Label Group expands RLG Healthcare business with acquisition of Beyer GraphicsMay 22, 2024 | finance.yahoo.comSixPeaks, a new obesity biotech, starts up with an option to sell to AstraZenecaMay 22, 2024 | markets.businessinsider.comHBM Healthcare Investments' portfolio company Swixx BioPharma boosts sales and profits through strategic acquisition in Latin AmericaMay 22, 2024 | finance.yahoo.comGenmab acquires biotechnology company ProfoundBio in $1.8bn dealMay 22, 2024 | msn.comKKR, Blackstone, Carlyle, Mankind Pharma eye acquisition of Advent-owned Bharat Serums & VaccinesMay 20, 2024 | msn.comAjooni Biotech Ltd's Rs 43.81 crores Rights opens on May 21, 2024May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ultragenyx Pharmaceutical Based on Clinical Updates and Market Valuation DisconnectMay 16, 2024 | msn.comJohnson & Johnson to buy dermatology-focused biotech ProteologixMay 16, 2024 | msn.comMankind Pharma: Strong Q4, Acquisition Reports Not Enough To Power StockMay 15, 2024 | bizjournals.comRaleigh clinical research firm expands in four states with acquisitionMay 15, 2024 | msn.comPharmaceutical giant Bayer AG trims workforce by 1500 amid slight sales declineMay 15, 2024 | msn.comBiopharmaceutical mergers and acquisitions surge to new highsMay 10, 2024 | bizjournals.comA second co-founder has left Forge Biologics following its more than $600M acquisitionMay 8, 2024 | bizjournals.comD.C. biotech mulling sweetened acquisition offerMay 8, 2024 | msn.comMyonex Expands Pharmaceutical Services with Acquisition of CreapharmMay 8, 2024 | finance.yahoo.comArbor Biotechnologies Announces Acquisition of SerendipityMay 3, 2024 | finance.yahoo.comEphicacy Consulting Group Completes Acquisition of Advance Research AssociatesMay 2, 2024 | bizjournals.comHow Moderna's cost-cutting moves hit a Bay Area biotechMay 1, 2024 | bizjournals.comAccounting giant wants to grow Albany footprint after Nuvalence acquisitionApril 29, 2024 | msn.comDeciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO PharmaceuticalApril 29, 2024 | markets.businessinsider.comDeciphera Up In Pre-market On News Of Acquisition By ONO Pharmaceutical For About $2.4 BlnApril 26, 2024 | msn.comEli Lilly’s acquisition of Nexus facility marks a new era for Pleasant Prairie’s pharmaceutical landscapeSee More Headlines Receive BIOT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biotech Acquisition and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BIOT CUSIPN/A CIK1825413 Webbioacq.com Phone212-227-1905FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.22% Return on Assets3.48% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.95) per share Price / Book-10.68Miscellaneous Outstanding Shares28,750,000Free Float23,288,000Market Cap$291.81 million OptionableNot Optionable Beta-0.12 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Michael Shleifer Ph.D. (Age 48)Chairman & CEO Mr. Thomas Fratacci (Age 44)CFO & Treasurer Mr. Ivan Jarry (Age 44)Chief Operating Officer Mr. Albert F. Hummel M.B.A. (Age 76)Chief Investment Officer & Director Key CompetitorsProthenaNASDAQ:PRTADay One BiopharmaceuticalsNASDAQ:DAWNLiquidiaNASDAQ:LQDABicycle TherapeuticsNASDAQ:BCYCCollegium PharmaceuticalNASDAQ:COLLView All Competitors This page (NASDAQ:BIOT) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biotech Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share Biotech Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.